References
- Binks S, Vincent A, Palace J. (2016). Myasthenia gravis: A clinical-immunological update. J Neurol, 263, 826–34.
- Christadoss P. (1989). Immunogenetics of experimental autoimmune myasthenia gravis. Crit Rev Immunol, 9, 247–78
- Deng C, Goluszko E, Tüzün E, et al. (2002). Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J Immunol, 169 1077–83.
- Ebrahimnezhad S, Amirghofran Z, Karimi MH. (2016). Decline in immunological responses mediated by dendritic cells in mice treated with 18α-glycyrrhetinic acid. Immunol Invest, 45, 191–204.
- Higuchi O, Hamuro J, Motomura M, Yamanashi Y. (2011). Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol, 69, 418–22.
- Klooster R, Plomp JJ, Huijbers MG, et al. (2012). Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain, 135, 1081–101.
- Koneczny I, Cossins J, Waters P, et al. (2013). MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. PLoS One, 8, e80695.
- Liu W, Almo SC, Zang X. (2016). Co-stimulate or co-inhibit regulatory T cells, which side to go? Immunol Invest, 45, 813–31.
- Otsuka K, Ito M, Ohkawara B, et al. (2015). Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling. Sci Rep, 5, 13928.
- Pevzner A, Schoser B, Peters K, et al. (2012). Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol, 259, 427–35.
- Preuss KD, Pfreundschuh M, Ahlgrimm M, et al. (2009). A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS. Int J Cancer, 125, 656–61.
- Ramroodi N, Khani M, Ganjali Z, et al. (2015). Prophylactic effect of BIO-1211 small-molecule antagonist of VLA-4 in the EAE mouse model of multiple sclerosis. Immunol Invest, 44, 694–712.
- Schaffert H, Pelz A, Saxena A, et al. (2015). IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis. Eur J Immunol, 45, 1339–47.
- Shen C, Lu Y, Zhang B, et al. (2013). Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest, 123, 5190–202.
- Tüzün E, Christadoss P. (2013). Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev, 12, 904–11.
- Wu B, Goluszko E, Huda R, Tüzün E, Christadoss P. (2013). Experimental autoimmune myasthenia gravis in the mouse. Curr Protoc Immunol, 100, 1–26.
- Wu H, Lu Y, Shen C, Patel N, et al. (2012). Distinct roles of muscle and motoneuron LRP4 in neuromuscular junction formation. Neuron, 75, 94–107.
- Yang H, Wu B, Tüzün E, et al. (2007). A new mouse model of autoimmune ocular myasthenia gravis. Invest Ophthalmol Vis Sci, 48, 5101–11.
- Zhang B, Tzartos JS, Belimezi M, et al. (2012). Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol, 69, 445–51.
- Zhang GX, Xiao BG, Bai XF, et al. 1999. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol, 162, 3775–81.